Indegene

Investment case

Pharma commercialisation outsourcing

Why this business

Indegene is the only India-listed pure-play provider of technology-led commercialisation services to life-sciences companies (medical/regulatory writing, omnichannel marketing, pharmacovigilance, MLR review), serving all of the world's top-20 biopharma firms plus 105 active clients (65 at IPO). FY26 revenue Rs 3,510 cr (+23.6%); North America 75%, Europe 22%; ~60% of revenue is output/outcome-priced rather than hourly. It has bolted on BioPharm Communications (USD 104 mn, Oct-2025), Cake Kommunikations (EUR 8.5 mn, Nov-2025) and WARN & Co (2026).

What we believe

1. 01Fastest-growing listed IT-services-type name: Q1FY27 revenue +39.7% (26.5% in USD), FY27 organic growth guided above FY26's 23.6%, with H2 acceleration from a USD 10 mn+ ACV outcome-based deal.
2. 02Margin recovery is dated: 16.9% EBITDA margin guided back to 19-20% by Q4FY27 as GTM investments stop and the omnichannel deal's already-incurred costs convert to revenue; IDBI models 29% EPS CAGR FY26-28.
3. 03Client base broadening: 105 active clients, USD 1 mn+ accounts 54 (27 at IPO), revenue beyond top-20 clients 33.4% (doubled YoY), NRR 105.8% organic.
4. 04AI is a margin lever, not just a threat: ~60% output/outcome-priced revenue means productivity from Cortex/NEXT (50-60% MLR-review cost savings) accrues to Indegene rather than being billed away.
5. 05Net cash Rs 1,460 cr (cash & investments) funds tuck-ins; ROCE 18.8% and ~21x FY28E EPS for 18% revenue CAGR (IDBI).

Why now

TTM PE 34.3x on a margin-trough year (FY26 EBITDA margin 17.6% vs ~19.5% in FY24); stock ~19% below its 52-week high at end-Jul-2026. Listed only since May-2024, so no 5-yr history. EV/EBITDA computed on mcap less Rs 1,316 cr net cash over FY26 EBITDA. EV/EBITDA 20.9x; dividend yield 0.4%.

Market disagreement

• Persistent Systems: Persistent grows at a similar ~23% but at a materially higher PE with generic-IT AI-deflation risk; Indegene grows faster in USD (26.5%) inside a regulated life-sciences niche at ~21x FY28E.
• Sagility: Sagility is US-healthcare payer/provider BPO with single-digit organic growth and PE-sponsor overhang; Indegene sells to pharma commercial/medical budgets with 105 clients and 105.8% NRR.

Position sizing

Core Small cap  1.2% of the PMS on $31 Jul 2026 (August rank 25). Core positions are owned through the cycle for leadership and cash-flow quality.

Catalysts

• Q3FY27 (Jan-2027): revenue recognition begins on the USD 10 mn+ ACV outcome-based omnichannel contract.
• Q4FY27 (Apr/May-2027): EBITDA margin back in the 19-20% band per guidance.
• Further tuck-in acquisitions using Rs 1,460 cr cash; expansion of the 'Tectonic' largest-client engagement from Germany/Spain to more markets.

Risks and response

• Client concentration: top-20 clients 72% of FY26 revenue; largest client >USD 50 mn run-rate; US drug-pricing/MFN policy cuts to pharma marketing budgets would hit demand.
• Margin execution: EBITDA margin fell from ~20% to 16.9%; employee costs +37% YoY; failure to reach 19-20% by Q4FY27 would compress the multiple.
• AI commoditisation of content/medical-writing workflows, and slower enterprise AI adoption than expected (flagged by management); acquisition integration (BioPharm USD 104 mn) and FX (75% North America).

Thesis-break conditions

Not stated separately on this page; the risk list carries the monitoring triggers.

Review history

• 8 Sep 2026 · Yash Palod · one-pager in "Why We Own What We Own" (p48) · portfolio as of $31 Jul 2026
• 31 Aug 2026 · Classification in the August top-30: Value (July book: Core)

Source: Buoyant_Why_We_Own_What_We_Own_Sep2026.pdf (portfolio as of 31 July 2026), p48. Internal; external publication of these fields is controlled by audience policy.